Saturna Capital Corp Cassava Sciences Inc Transaction History

Saturna Capital Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$17.22 - $38.47 $643,597 - $1.44 Million	-37,375 Reduced 70.02%	16,000 $450,000
Q1 2022 May 10, 2022	SELL	$32.6 - $53.05 $68,460 - $111,405	-2,100 Reduced 3.79%	53,375 $1.98 Million
Q4 2021 Feb 09, 2022	BUY	$36.77 - $90.91 $2,757 - $6,818	75 Added 0.14%	55,475 $2.42 Million
Q3 2021 Nov 08, 2021	BUY	$41.79 - $135.3 $12,537 - $40,590	300 Added 0.54%	55,400 $3.44 Million
Q1 2021 May 14, 2021	BUY	$7.09 - $87.95 $248,859 - $3.09 Million	35,100 Added 175.5%	55,100 $2.48 Million
Q4 2020 Feb 12, 2021	BUY	$6.79 - $12.25 $135,800 - $245,000	20,000 New	20,000 $136,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Saturna Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Saturna Capital Corp with notifications on news.